跳至主導覽 跳至搜尋 跳過主要內容

Differential predictive value of FRAX Hip and major osteoporotic fracture probabilities for denosumab response

  • Wei Cheng Huang
  • , Chao Tung Chen
  • , Jia Feng Chen
  • , Shan Fu Yu
  • , Chung Yuan Hsu
  • , Ying Chou Chen*
  • *此作品的通信作者
  • Chang Gung University
  • Chang Gung Memorial Hospital

研究成果: 期刊稿件 › 文章 › 同儕審查

摘要

Introduction: The Fracture Risk Assessment Tool (FRAX) estimates 10-year probabilities of major osteoporotic fracture (MOF) and hip fracture. Whether these two components differentially predict response to denosumab remains unclear. Objectives: To determine whether baseline FRAX-MOF and FRAX-hip probabilities show opposing associations with 1-year bone mineral density (BMD) improvement after denosumab. Methods: Patients with osteoporosis who had BMD measured at baseline and 12 months after initiating denosumab were enrolled. Clinical risk factors were obtained by structured interview, and Taiwan-specific FRAX probabilities for MOF and hip fracture were calculated. Logistic regression examined the association between each FRAX probability and BMD improvement (primary outcome). Results: Among 150 denosumab-treated patients, a higher FRAX-MOF probability was associated with a lower likelihood of BMD improvement (P = 0.011; OR 0.81; 95% CI 0.68–0.95), whereas a higher FRAX-hip probability was associated with a greater likelihood of improvement (P ' 0.001; OR 1.74; 95% CI 1.30–2.34). Conclusion: FRAX components convey differential predictive information for denosumab response: higher FRAX-hip probability predicts benefit, while higher FRAX-MOF probability predicts attenuated BMD gain. Recognizing these opposing directions may refine patient selection and expectation-setting for denosumab in osteoporosis care. Mini-Abstract: This study shows that fracture risk scores predict denosumab response differently: hip fracture risk predicts stronger bone density gains, while major osteoporotic fracture risk predicts weaker gains. Recognizing these opposing signals can improve patient selection and treatment expectations in osteoporosis management.

原文英語
文章編號101672
期刊Journal of Clinical Densitometry
卷29
發行號2
DOIs
出版品狀態已出版 - 01 04 2026

文獻附註

Publisher Copyright:
Copyright © 2026. Published by Elsevier Inc.

指紋

深入研究「Differential predictive value of FRAX Hip and major osteoporotic fracture probabilities for denosumab response」主題。共同形成了獨特的指紋。

引用此